* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Admissions:
None
Delistings:
On Friday 23rd January, Indus Gas Limited (INDI.L) left AIM
What’s baking in the oven?
IPOs:***
14th January: Roundhouse Digital, an operational AI services business with complementary strategic treasury management (Ethereum denominated), has announced its intention to IPO onto AQSE. Offer details TBC and expected Admission date 27 January.
Market Movers:***
14 January: GlobalData (DATA.L), the data, insight, and technology Companyexpects to submit its application to move to the Main Market from AIM and to take place on 5 March.
12th January: The Smarter Web Company (AQSE:SWC) announces its intention to cancel its Admission to trading of its ordinary shares on the Aquis Growth Market and seek Admission onto the Main Market. Subject to shareholder approval, the Cancellation and Admission are expected to take place on 3 February.
11th November: CVS Group (CVSG.L) announced its plan to move from AIM to the Main Market on 29 January, subject to FCA approval of a prospectus and the ordinary shares being admitted by the FCA to the Main Market. The Group does not intend to raise funds in connection with the move.
Reverse Takeover:***
31st December: Ovoca (OVB.L) announced a reverse takeover of Tadeen, a UK-registered Company, which indirectly owns 100% of the Licences in Morocco, prospective for Copper and Silver through its wholly owned subsidiary, Horizons Mines SARL. Capital to be raised on Admission is £1.155m with an anticipated market capitalisation on Admission of approximately £4.9m. Expected Admission date is 28th January.
Banquet Buffet****
Andrada Mining 4.65p £89.7m (ATM.L)
The tin producer with a portfolio of critical minerals mining and exploration assets in Namibia, announced surface sampling results from Lithium Ridge in partnership with Sociedad Quimica y Minera de Chile SA through its subsidiary SQM Australia (Pty) Ltd. The results of the comprehensive geological mapping and grab sampling across the licence area provide strong validation for the ongoing Stage 1 drilling programme, funded by SQM under the previously announced earn-in agreement, to acquire a 30% shareholding.
Highlights included multiple grab samples returned grades that exceeded 4% Li2O, with a peak value of 4.67% Li2O.
Botswana Diamonds 0.325p £3.9m (BOD.L)
The multi-commodity and diamond explorer focused on Botswana announced the award of eight prospecting licences covering approximately 7,000 square kilometres in north-western Botswana. The licence areas, which are valid through to 31st December 2028, were selected following an extensive AI-driven assessment of the Company's 95,000 square kilometres (including 375,000 line kilometres of geophysics) Botswana focused exploration database, which identified significant prospectivity for copper, with additional potential for gold and other critical minerals. Application of the same proprietary technology to diamond exploration has previously highlighted six previously unreported kimberlite-prone areas, over which the Company also holds licences.
DeFi Development Corporation 73.5p £3.8m (DFDV.L)
The Main Market listed company which offers both an AI agent platform that enables businesses to automate tasks through the use of specialised digital workers for sales, recruitment and research as well as a SOL treasury, announced that it has entered into a revolving credit facility agreement with DeFi Development Corp. Under the terms of the Facility, the Lender has agreed to make available to the Company a revolving credit facility of up to US$4.75m. The Facility has a term of 36 months from the date of the agreement, with availability ending one month prior to final maturity. Amounts drawn under the Facility will bear interest at a rate of 10 per cent. per annum, calculated on a daily basis.
Georgina Energy 4.95p £6.3m (GEX.L)
The helium, hydrogen and natural resources development and production company advises that Harlequin Energy Ltd has formally confirmed its intention to proceed with funding for the Hussar EP513 prospect for the anticipated recovery of Helium, Hydrogen and Natural Gas. Harlequin has given notice to proceed with funding of the drilling of the Hussar-2 well within the EP513 Lease and undertaken to complete site repairs to the airstrip and access roads, construction of drilling pads, water wells and camp location pad, in preparation for drilling as set out in the Memorandum of Understanding signed on 24th August 2024. The Company has undertaken due diligence and been provided with Harlequin's USD$25m structured offtake funding facility to finance Georgina's drilling program.
Harena Rare Earths 2.15p £12.7m (HREE.L)
Harena Rare Earths Plc (formerly Citius Resources), the rare earths company focused on the Ampasindava ionic clay rare earth project in Madagascar, announced the highlights from its completed pre-feasibility study (PFS). The PFS represents an important advancement in the development of the Ampasindava Project, confirming its technical viability and providing a robust economic and operational framework to support the next phase of project progression. The PFS was compiled by the Company with global engineering group SGS engaged to support technical inputs to the PFS and also to conduct an update of the 2023 Mineral Resource Estimate to JORC 2012 standard. The highlights included total rare earth oxide (TREO1) of ~71kt, over a measured 20-year life of mine, total rare earth oxide of ~71kt, over a measured 20-year life of mine while plant throughput was set at 5Mtpa (dry) at an average grade at 1,500 ppm TREO supported by independent metallurgical test work.
IMC Exploration Group 0.6p £4.7m (IMC.L)
The Irish exploration company has announced the renewal of its mining licence to Assat LLC, IMC's 100% owned subsidiary, for the Karaberd Mine, located in Lori Marz province Republic of Armenia. The licence has been renewed for a period of 9 years until 1st January 2035. The renewed licence provides for underground extraction of 30,000 tons of ore per annum and a requirement to submit a reserve revaluation report to the authorized body two years after receiving the right to use the subsoil, which should also include the reserves available in the open pit. Under the renewed Licence Assat LLC has a right to extract up to 1,274 kg of gold and 2,310 kg of silver. The extended tenure of the licence to 2035 secures the long-term future of the mine and enables the systematic extraction of the ore that will be processed to extract Gold and Silver.
Oriole Resources 0.37p £18m (ORR.L)
The AIM quoted gold exploration company focused on West and Central Africa, provided an update on its 90% owned Mbe gold project in Cameroon, where it has received further results from the ongoing 2,950m maiden diamond drilling programme at the MB01-N target. Highlights included hole MBDD027 recording gold intersections including 16.10m at 2.49g/t Au from 152.40m, including 1.00m at 28.60g/t Au from 159.50m and 2.00m at 6.57g/t Au from 52.00m, including 1.00m at 12.90g/t Au. The mineralisation in MBDD027 is interpreted to be the along strike continuation of reported mineralisation in hole MBDD026, 100m to the north. MBDD027 has also confirmed the system at MB01-N to at least 160m vertical depth from surface.
PHSC 10.5p £1.1m (PHSC.L)
The provider of health, safety and quality systems consultancy and training services and security solutions to the public and private sectors, announced the disposal on 23 January 2026 of the group's freehold property at Raunds, Northamptonshire for gross cash proceeds of approximately £191k. The Raunds Office has previously been used by the group's wholly owned subsidiaries, RSA Environmental Health Ltd and Quality Leisure Management Ltd. Following changes in working patterns since the pandemic, it has been under-utilised and is no longer required for day-to-day operations. Its disposal allows the Group to reinvest capital into areas that support growth, capability, and operational development.
Theracryf 0.12p £4.51m (TCF.L)
The biotech company developing new medicines for addiction and other disorders of the brain, updates on preclinical development. It has received a Notice of Allowance from the Canadian Patent Office for its Orexin-1 (Ox-1) addiction programme. The patent provides Composition of Matter, the strongest form of patent cover available, conferring long-term exclusivity and significantly strengthening the commercial and partnering proposition for the programme. There is progress on its Maximum Tolerated Dose (MTD) and Dose Range Finding (DRF) studies. The MTD have now been successfully completed with no adverse clinical observations reported. These de-risk the programme and enables progression into repeat-dose DRF studies, the results will inform the regulatory toxicity studies scheduled in Q1 and Q2 2026. This is a near final step on the path to IND/CTA readiness targeted for 2026.
Venture Life Group 65.75p £82.39m (VLG.L)
The international consumer self-care company announced a trading update for the twelve-month period ended 31 December 2025. The accounting date has been changed from 31 December to 31 May and will publish unaudited interim accounts for 31 March 2026. Revenues are 32% ahead at £35.1m compared to the previous year. Following the disposal of its CDMO operations (Contract Development Manufacturing Organisation), VLG is now a pure branded consumer healthcare business, focused on the growth and development of its brands. The growth in revenues came from increases to Balance Activ of 37.0% to £7.3m and Earol of 11.5% to £3.2m. The Health & Her/Him brands, which were acquired on 8 November 2024, delivered significant proforma growth of 44%, reaching £8.5m. The net cash is £34.4m compared to £34.1m in September 2025. The Company's share buyback programme continues and a total of £1.1m had been returned to shareholders. The Board remains confident of achieving revenue and EBITDA expectations for the seventeen-month accounting period ending 31 May 2026.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
